These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 22039286)

  • 21. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
    Harris LN; Yang L; Tang C; Yang D; Lupu R
    Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of HER2 detection methods between central and regional laboratories in Greece.
    Papadopoulos S; Kouvatseas G; Skarlos D; Malamos N; Delliou E; Saratsiotou I; Ardavanis A; Mavroudis D; Skarpidi E; Arapantoni P; Karyda I; Patakioyta F; Aravantinos G; Razis E; Fountzilas G; Kosmidis P
    Clin Breast Cancer; 2007 Oct; 7(10):784-90. PubMed ID: 18021480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating HER2 amplification and overexpression in breast cancer.
    Bartlett JM; Going JJ; Mallon EA; Watters AD; Reeves JR; Stanton P; Richmond J; Donald B; Ferrier R; Cooke TG
    J Pathol; 2001 Nov; 195(4):422-8. PubMed ID: 11745673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH).
    Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY
    Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 gene status in primary breast cancers and matched distant metastases.
    Tapia C; Savic S; Wagner U; Schönegg R; Novotny H; Grilli B; Herzog M; Barascud AD; Zlobec I; Cathomas G; Terracciano L; Feichter G; Bubendorf L
    Breast Cancer Res; 2007; 9(3):R31. PubMed ID: 17511881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
    López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
    Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
    Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
    Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
    Torrisi R; Rotmensz N; Bagnardi V; Viale G; Curto BD; Dell'orto P; Veronesi P; Luini A; D'Alessandro C; Cardillo A; Goldhirsch A; Colleoni M
    Eur J Cancer; 2007 Nov; 43(16):2339-44. PubMed ID: 17855075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
    Park IH; Kwon Y; Ro JY; Lee KS; Ro J
    Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Pathvysion and Poseidon HER2 FISH assays in measuring HER2 amplification in breast cancer: a validation study.
    Francz M; Egervari K; Kardos L; Toth J; Nemes Z; Szanto J; Szollosi Z
    J Clin Pathol; 2010 Apr; 63(4):341-6. PubMed ID: 19965795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of HER2/neu gene amplification in patients with invasive breast carcinoma. Comparison of in situ hybridization methods.
    Sińczak-Kuta A; Tomaszewska R; Rudnicka-Sosin L; Okoń K; Stachura J
    Pol J Pathol; 2007; 58(1):41-50. PubMed ID: 17585541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection.
    Moelans CB; de Weger RA; Ezendam C; van Diest PJ
    BMC Cancer; 2009 Jan; 9():4. PubMed ID: 19123950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer.
    Purnomosari D; Aryandono T; Setiaji K; Nugraha SB; Pals G; van Diest PJ
    Biotech Histochem; 2006; 81(2-3):79-85. PubMed ID: 16908432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
    Bartlett JM; Campbell FM; Mallon EA
    Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The correlation between dual-color chromogenic in situ hybridization and fluorescence in situ hybridization in assessing HER2 gene amplification in breast cancer.
    Pedersen M; Rasmussen BB
    Diagn Mol Pathol; 2009 Jun; 18(2):96-102. PubMed ID: 19430295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.